Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D9RH0V
|
|||
Drug Name |
DCC-3014
|
|||
Synonyms |
Vimseltinib; UNII-PX9FTM69BF; PX9FTM69BF; DCC3014; 1628606-05-2; 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one; 3-methyl-5-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-(propan-2-ylamino)pyrimidin-4-one; Vimseltinib [INN]; SCHEMBL16047448; GTPL11190; EX-A4700; NSC828316; NSC-828316; example 10 [WO2014145025A2]; HY-136256; CS-0121044; 3-Methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-4(3H)-pyrimidinone; 4(3H)-Pyrimidinone, 3-methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1/2 | [1] | |
Company |
Deciphera Pharmaceuticals
|
|||
Structure |
Download2D MOL |
|||
Formula |
C23H25N7O2
|
|||
Canonical SMILES |
CC1=C(C=CC(=N1)C2=CN=C(N(C2=O)C)NC(C)C)OC3=CC(=NC=C3)C4=CN(N=C4)C
|
|||
InChI |
1S/C23H25N7O2/c1-14(2)27-23-25-12-18(22(31)30(23)5)19-6-7-21(15(3)28-19)32-17-8-9-24-20(10-17)16-11-26-29(4)13-16/h6-14H,1-5H3,(H,25,27)
|
|||
InChIKey |
TVGAHWWPABTBCX-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 1628606-05-2
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Macrophage colony-stimulating factor 1 receptor (CSF1R) | Target Info | Inhibitor | [2] |
KEGG Pathway | MAPK signaling pathway | |||
Ras signaling pathway | ||||
Rap1 signaling pathway | ||||
Cytokine-cytokine receptor interaction | ||||
Viral protein interaction with cytokine and cytokine receptor | ||||
PI3K-Akt signaling pathway | ||||
Osteoclast differentiation | ||||
Hematopoietic cell lineage | ||||
Pathways in cancer | ||||
Transcriptional misregulation in cancer | ||||
Acute myeloid leukemia |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT03069469) Study of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor. U.S. National Institutes of Health. | |||
REF 2 | Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.